Real-world effectiveness and tolerability of dienogest in patients with endometriosis: a cross-sectional patient-reported-study

Prost P, Pauline Prost, Marjorie Pierre, Pierre M, Allègre L, Lucie Allègre, Bottero C, Célia Bottero, V. Letouzey, LETOUZEY V, Vincent Letouzey, Stéphanie Huberlant, Huberlant S
Journal of gynecology obstetrics and human reproduction · 2026 · vol. 55(9) , pp. 103272 · doi:10.1016/j.jogoh.2026.103272 · PMID:42692407 · W7207712735
Observational OA: hybrid public-domain-us
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-20 ⓘ

This cross-sectional study of 146 endometriosis patients found that dienogest significantly improved dysmenorrhea and quality of life, though frequent adverse events led to high discontinuation rates.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the effectiveness and tolerability of dienogest in patients with endometriosis in real-world clinical practice. METHODS: This cross-sectional observational study was based on a self-administered questionnaire in which patients retrospectively reported their symptoms and quality of life before dienogest initiation, as well as perceived treatment effectiveness and tolerability. The questionnaire was distributed to patients followed for endometriosis within a regional endometriosis care network (April 2024-September 2025). Participants assessed symptom improvement, overall quality of life before and during treatment, the frequency of adverse events, and treatment continuation or discontinuation. Changes in quality of life before and after treatment were analysed using the Wilcoxon test. RESULTS: A total of 146 patients were included. Complete resolution of dysmenorrhea was reported by 44.7% of patients with baseline dysmenorrhea (55/123). Overall quality of life significantly improved under treatment (4.4 ± 2.3 vs 5.5 ± 2.6; p < 0.001). All patients reported at least one adverse event; the most frequent were fatigue (63.0%), decreased libido (58.3%), and mood disturbances (50.7%). Treatment was discontinued by 40.4% of patients, mainly due to adverse events. Some symptom improvements and adverse events varied according to treatment duration. CONCLUSIONS: In this real-world patient-reported study, patients reported improvement under dienogest treatment, particularly for dysmenorrhea and overall quality of life. However, frequent adverse events and treatment discontinuation suggest that tolerability may limit long-term adherence.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (18)

SciLite annotations

chemicals 4
dienogest dienogest dienogest dienogest

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-10-15T06:00:39.803327+00:00
pubmed
last seen: 2026-10-15T06:02:21.945644+00:00
scilite
last seen: 2026-09-20T10:02:19.494152+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine